Exact Mass: 532.2373

12alpha-Hydroxyamoorstatin

C28H36O10 (532.2308)

Nomilinic acid

C28H36O10 (532.2308)

Nomilinic acid is found in citrus. Nomilinic acid is a constituent of grapefruit seeds

Austalide E

C28H36O10 (532.2308)

Austalide E is a metabolite of Aspergillus ustus. Metabolite of Aspergillus ustus.

Austalide D

C28H36O10 (532.2308)

Austalide D is a metabolite of Aspergillus ustu Metabolite of Aspergillus ustus.

Ponatinib

C29H27F3N6O (532.2198)

Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents

Dehydroandrographolide succinate

C28H36O10 (532.2308)

PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C25H41O10P (532.2437)

PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C25H41O10P (532.2437)

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C25H41O10P (532.2437)

PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C25H41O10P (532.2437)

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C25H41O10P (532.2437)

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Dehydroandrographolidesuccinate

C28H36O10 (532.2308)

Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1]. Dehydroandrographolide succinate, extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1].

[3R-(3alpha,5beta,5aalpha,6alpha,7alpha,9alpha,9aalpha,10R*)]-Octahydro-5a-(hydroxymethyl)-2,2,9-trimethyl-, 6,7,10-triacetate 5-benzoate 2H-3,9a-methano-1-benzoxepin-5,6,7,10-tetrol

C28H36O10 (532.2308)

Esulatin E

C28H36O10 (532.2308)

Ejap 10

C28H36O10 (532.2308)

Echitoserpidine

C30H32N2O7 (532.2209)

Celahin C

C28H36O10 (532.2308)

Zizyvoside I

C25H40O12 (532.252)

[3R-(3alpha,5beta,5aalpha,6alpha,9beta,9aalpha,10R*)]-5a-[(Acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-5,6,9,10-tetrol 5,10-diacetate 6-benzoate

C28H36O10 (532.2308)

Salasol A

C28H36O10 (532.2308)

AC1LADZQ

C28H36O10 (532.2308)

Kadcoccilactone J

C28H36O10 (532.2308)

Rzedowskin A

C28H36O10 (532.2308)

[3R-(3alpha,4beta,5alpha,5aalpha,6alpha,9beta,9aalpha,10R*)]-Octahydro-2,2,5a,9-tetramethyl-, 4,5,10-triacetate 6-benzoate 2H-3,9a-methano-1-benzoxepin-4,5,6,9,10-pentol

C28H36O10 (532.2308)

Nomilinoate A-ring lactone

C28H36O10 (532.2308)

C30H32N2O7

C30H32N2O7 (532.2209)

Angulatueoid C

C28H36O10 (532.2308)

(1S,4S,5S,6R,7R,9S,10S)-9-benzoyloxy-1,6,15-triacetoxy-4-hydroxy-dihydro-beta-agarofuran|9-Benzoyl,1,6,14-tri-Ac-(1alpha,4beta,6beta,9beta)-1,4,6,8,14-Pentahydroxydihydro-beta-agarofuran

C28H36O10 (532.2308)

wuweizidilactone H

C28H36O10 (532.2308)

bistratamide F

C25H36N6O5S (532.2468)

A homodetic cyclic peptide that consists of L-threonine and L-valine and L-serine as the amino acid residues cyclised via amide bonds. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line

4-[(beta-D-glucopyranosyl)oxy]-2-(hydroxymethyl)-3-(3-methylbut-2-en-1-yl)phenyl beta-D-glucopyranoside|clemomandshuricoside C

C24H36O13 (532.2156)

(9R)-2beta,9-dihydroxymegastigma-4,7-dien-3-one 9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside

C25H40O12 (532.252)

6beta,9beta,14-Triacetoxy-1alpha-benzoyloxy-4beta-hydroxydihydro-beta-agarofuran

C28H36O10 (532.2308)

C28H36O10

C28H36O10 (532.2308)

turrapubesic acid A

C28H36O10 (532.2308)

chabamide H

C31H36N2O6 (532.2573)

(6S,7R,Ra)-3-phenylacrylic acid 2,3,10,11,12-pentamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cycloocten-1-yl ester|neglschisandrin A

C32H36O7 (532.2461)

Isomorellinol

C32H36O7 (532.2461)

chabamide I

C31H36N2O6 (532.2573)

(6R,9R)-3-oxo-alpha-ionol-9-O-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranoside

C25H40O12 (532.252)

C25H40O12

C25H40O12 (532.252)

aspergillide C|aspergillipeptide C

C26H36N4O8 (532.2533)

(1S,4S,5S,6R,7R,9S,10S)-1,6,15-triacetoxy-9-benzoyloxy-4-hydroxy-8-oxo-dihydro-beta-agarofuran

C28H36O10 (532.2308)

balgacyclamide A

C25H36N6O5S (532.2468)

illihenlactone B

C24H36O13 (532.2156)

klymollin K

C26H41ClO9 (532.2439)

caesall E

C28H36O10 (532.2308)

excavatoid H

C28H36O10 (532.2308)

eucalmainoside D

C24H36O13 (532.2156)

C36H36O4

C36H36O4 (532.2613)

Satratoxin G

C28H36O10 (532.2308)

2,7-Dihydroxy-2,8-dimethyl-4-vinyl-11-(2,8-dimethyl-7-hydroxy-9,10-dihydrophenanthrene-3-yl)-1,4-ethano-1,2,3,4,9,10-hexahydrophenanthrene-3-one

C36H36O4 (532.2613)

alstiphyllanine E

C30H32N2O7 (532.2209)

eucalmainoside E

C24H36O13 (532.2156)

(1alpha,2alpha,8beta,9beta)-2,8,14-tris(acetyloxy)-9-(benzoyloxy)-1-hydroxydihydro-beta-agarofuran|rel-5a-[(acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,7-diacetate 5-benzoate

C28H36O10 (532.2308)

12-Oxo-2beta,3beta-di-O-acetyl-5beta,11alpha-dihydroxybufalin

C28H36O10 (532.2308)

12-hydroxyamoorastatone|12alpha-hydroxyamoorastatone|isochuanliansu

C28H36O10 (532.2308)

Thr Arg Gln Glu

C20H36N8O9 (532.2605)

Pro Thr Val Asn Cys

C21H36N6O8S (532.2315)

His Val Tyr Asp

C24H32N6O8 (532.2282)

Ala Ser Asn Asp Leu

C21H36N6O10 (532.2493)

Asn Asp Glu Arg

C19H32N8O10 (532.2241)

Sunitinib Malate (Sutent)

C26H33FN4O7 (532.2333)

Ponatinib (AP24534)

C29H27F3N6O (532.2198)

C28H36O10_2-Hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0~1,17~.0~4,16~.0~6,14~.0~8,12~]tricosa-6(14),7,12-trien-18-yl acetate

C28H36O10 (532.2308)

Ala Ala Trp Trp

C28H32N6O5 (532.2434)

Ala Glu Gln Trp

C24H32N6O8 (532.2282)

Ala Glu Trp Gln

C24H32N6O8 (532.2282)

Ala Gln Glu Trp

C24H32N6O8 (532.2282)

Ala Gln Trp Glu

C24H32N6O8 (532.2282)

Ala Trp Ala Trp

C28H32N6O5 (532.2434)

Ala Trp Glu Gln

C24H32N6O8 (532.2282)

Ala Trp Gln Glu

C24H32N6O8 (532.2282)

Ala Trp Trp Ala

C28H32N6O5 (532.2434)

Cys Lys Pro Trp

C25H36N6O5S (532.2468)

Cys Lys Trp Pro

C25H36N6O5S (532.2468)

Cys Pro Lys Trp

C25H36N6O5S (532.2468)

Cys Pro Trp Lys

C25H36N6O5S (532.2468)

Cys Trp Lys Pro

C25H36N6O5S (532.2468)

Cys Trp Pro Lys

C25H36N6O5S (532.2468)

Asp Asp Lys Arg

C20H36N8O9 (532.2605)

Asp Asp Gln Arg

C19H32N8O10 (532.2241)

Asp Asp Arg Lys

C20H36N8O9 (532.2605)

Asp Asp Arg Gln

C19H32N8O10 (532.2241)

Asp Glu Asn Arg

C19H32N8O10 (532.2241)

Asp Glu Arg Asn

C19H32N8O10 (532.2241)

Asp Gly Arg Trp

C23H32N8O7 (532.2394)

Asp Gly Trp Arg

C23H32N8O7 (532.2394)

Asp His Val Tyr

C24H32N6O8 (532.2282)

Asp His Tyr Val

C24H32N6O8 (532.2282)

Asp Lys Asp Arg

C20H36N8O9 (532.2605)

Asp Lys Arg Asp

C20H36N8O9 (532.2605)

Asp Asn Glu Arg

C19H32N8O10 (532.2241)

Asp Asn Arg Glu

C19H32N8O10 (532.2241)

Asp Asn Val Trp

C24H32N6O8 (532.2282)

Asp Asn Trp Val

C24H32N6O8 (532.2282)

Asp Gln Asp Arg

C19H32N8O10 (532.2241)

Asp Gln Arg Asp

C19H32N8O10 (532.2241)

Asp Arg Asp Lys

C20H36N8O9 (532.2605)

Asp Arg Asp Gln

C19H32N8O10 (532.2241)

Asp Arg Glu Asn

C19H32N8O10 (532.2241)

Asp Arg Gly Trp

C23H32N8O7 (532.2394)

Asp Arg Lys Asp

C20H36N8O9 (532.2605)

Asp Arg Asn Glu

C19H32N8O10 (532.2241)

Asp Arg Gln Asp

C19H32N8O10 (532.2241)

Asp Arg Trp Gly

C23H32N8O7 (532.2394)

Asp Val His Tyr

C24H32N6O8 (532.2282)

Asp Val Asn Trp

C24H32N6O8 (532.2282)

Asp Val Trp Asn

C24H32N6O8 (532.2282)

Asp Val Tyr His

C24H32N6O8 (532.2282)

Asp Trp Gly Arg

C23H32N8O7 (532.2394)

Asp Trp Asn Val

C24H32N6O8 (532.2282)

Asp Trp Arg Gly

C23H32N8O7 (532.2394)

Asp Trp Val Asn

C24H32N6O8 (532.2282)

Asp Tyr His Val

C24H32N6O8 (532.2282)

Asp Tyr Val His

C24H32N6O8 (532.2282)

Glu Ala Gln Trp

C24H32N6O8 (532.2282)

Glu Ala Trp Gln

C24H32N6O8 (532.2282)

Glu Asp Asn Arg

C19H32N8O10 (532.2241)

Glu Asp Arg Asn

C19H32N8O10 (532.2241)

Glu Glu Lys Gln

C21H36N6O10 (532.2493)

Glu Glu Gln Lys

C21H36N6O10 (532.2493)

Glu Phe His Thr

C24H32N6O8 (532.2282)

Glu Phe Thr His

C24H32N6O8 (532.2282)

Glu His Phe Thr

C24H32N6O8 (532.2282)

Glu His Thr Phe

C24H32N6O8 (532.2282)

Glu Lys Glu Gln

C21H36N6O10 (532.2493)

Glu Lys Gln Glu

C21H36N6O10 (532.2493)

Glu Asn Asp Arg

C19H32N8O10 (532.2241)

Glu Asn Arg Asp

C19H32N8O10 (532.2241)

Glu Gln Ala Trp

C24H32N6O8 (532.2282)

Glu Gln Glu Lys

C21H36N6O10 (532.2493)

Glu Gln Lys Glu

C21H36N6O10 (532.2493)

Glu Gln Arg Thr

C20H36N8O9 (532.2605)

Glu Gln Thr Arg

C20H36N8O9 (532.2605)

Glu Gln Trp Ala

C24H32N6O8 (532.2282)

Glu Arg Asp Asn

C19H32N8O10 (532.2241)

Glu Arg Asn Asp

C19H32N8O10 (532.2241)

Glu Arg Gln Thr

C20H36N8O9 (532.2605)

Glu Arg Thr Gln

C20H36N8O9 (532.2605)

Glu Thr Phe His

C24H32N6O8 (532.2282)

Glu Thr His Phe

C24H32N6O8 (532.2282)

Glu Thr Gln Arg

C20H36N8O9 (532.2605)

Glu Thr Arg Gln

C20H36N8O9 (532.2605)

Glu Trp Ala Gln

C24H32N6O8 (532.2282)

Glu Trp Gln Ala

C24H32N6O8 (532.2282)

Phe Glu His Thr

C24H32N6O8 (532.2282)

Phe Glu Thr His

C24H32N6O8 (532.2282)

Phe Phe Gly Tyr

C29H32N4O6 (532.2322)

Phe Phe Tyr Gly

C29H32N4O6 (532.2322)

Phe Gly Phe Tyr

C29H32N4O6 (532.2322)

Phe Gly Tyr Phe

C29H32N4O6 (532.2322)

Phe His Glu Thr

C24H32N6O8 (532.2282)

Phe His Met Val

C25H36N6O5S (532.2468)

Phe His Thr Glu

C24H32N6O8 (532.2282)

Phe His Val Met

C25H36N6O5S (532.2468)

Phe Met His Val

C25H36N6O5S (532.2468)

Phe Met Val His

C25H36N6O5S (532.2468)

Phe Thr Glu His

C24H32N6O8 (532.2282)

Phe Thr His Glu

C24H32N6O8 (532.2282)

Phe Val His Met

C25H36N6O5S (532.2468)

Phe Val Met His

C25H36N6O5S (532.2468)

Phe Tyr Phe Gly

C29H32N4O6 (532.2322)

Phe Tyr Gly Phe

C29H32N4O6 (532.2322)

Gly Asp Arg Trp

C23H32N8O7 (532.2394)

Gly Asp Trp Arg

C23H32N8O7 (532.2394)

Gly Phe Phe Tyr

C29H32N4O6 (532.2322)

Gly Phe Tyr Phe

C29H32N4O6 (532.2322)

Gly Arg Asp Trp

C23H32N8O7 (532.2394)

Gly Arg Trp Asp

C23H32N8O7 (532.2394)

Gly Trp Asp Arg

C23H32N8O7 (532.2394)

Gly Trp Arg Asp

C23H32N8O7 (532.2394)

Gly Tyr Phe Phe

C29H32N4O6 (532.2322)

His Asp Val Tyr

C24H32N6O8 (532.2282)

His Asp Tyr Val

C24H32N6O8 (532.2282)

His Glu Phe Thr

C24H32N6O8 (532.2282)

His Glu Thr Phe

C24H32N6O8 (532.2282)

His Phe Glu Thr

C24H32N6O8 (532.2282)

His Phe Met Val

C25H36N6O5S (532.2468)

His Phe Thr Glu

C24H32N6O8 (532.2282)

His Phe Val Met

C25H36N6O5S (532.2468)

His Met Phe Val

C25H36N6O5S (532.2468)

His Met Val Phe

C25H36N6O5S (532.2468)

His Thr Glu Phe

C24H32N6O8 (532.2282)

His Thr Phe Glu

C24H32N6O8 (532.2282)

His Val Asp Tyr

C24H32N6O8 (532.2282)

His Val Phe Met

C25H36N6O5S (532.2468)

His Val Met Phe

C25H36N6O5S (532.2468)

His Tyr Asp Val

C24H32N6O8 (532.2282)

His Tyr Val Asp

C24H32N6O8 (532.2282)

Lys Cys Pro Trp

C25H36N6O5S (532.2468)

Lys Cys Trp Pro

C25H36N6O5S (532.2468)

Lys Asp Asp Arg

C20H36N8O9 (532.2605)

Lys Asp Arg Asp

C20H36N8O9 (532.2605)

Lys Glu Glu Gln

C21H36N6O10 (532.2493)

Lys Glu Gln Glu

C21H36N6O10 (532.2493)

Lys Pro Cys Trp

C25H36N6O5S (532.2468)

Lys Pro Trp Cys

C25H36N6O5S (532.2468)

Lys Gln Glu Glu

C21H36N6O10 (532.2493)

Lys Arg Asp Asp

C20H36N8O9 (532.2605)

Lys Trp Cys Pro

C25H36N6O5S (532.2468)

Lys Trp Pro Cys

C25H36N6O5S (532.2468)

Met Phe His Val

C25H36N6O5S (532.2468)

Met Phe Val His

C25H36N6O5S (532.2468)

Met His Phe Val

C25H36N6O5S (532.2468)

Met His Val Phe

C25H36N6O5S (532.2468)

Met Val Phe His

C25H36N6O5S (532.2468)

Met Val His Phe

C25H36N6O5S (532.2468)

Asn Asp Arg Glu

C19H32N8O10 (532.2241)

Asn Asp Val Trp

C24H32N6O8 (532.2282)

Asn Asp Trp Val

C24H32N6O8 (532.2282)

Asn Glu Asp Arg

C19H32N8O10 (532.2241)

Asn Glu Arg Asp

C19H32N8O10 (532.2241)

Asn Arg Asp Glu

C19H32N8O10 (532.2241)

Asn Arg Glu Asp

C19H32N8O10 (532.2241)

Asn Val Asp Trp

C24H32N6O8 (532.2282)

Asn Val Trp Asp

C24H32N6O8 (532.2282)

Asn Trp Asp Val

C24H32N6O8 (532.2282)

Asn Trp Val Asp

C24H32N6O8 (532.2282)

Pro Cys Lys Trp

C25H36N6O5S (532.2468)

Pro Cys Trp Lys

C25H36N6O5S (532.2468)

Pro Lys Cys Trp

C25H36N6O5S (532.2468)

Pro Lys Trp Cys

C25H36N6O5S (532.2468)

Pro Trp Cys Lys

C25H36N6O5S (532.2468)

Pro Trp Lys Cys

C25H36N6O5S (532.2468)

Gln Ala Glu Trp

C24H32N6O8 (532.2282)

Gln Ala Trp Glu

C24H32N6O8 (532.2282)

Gln Asp Asp Arg

C19H32N8O10 (532.2241)

Gln Asp Arg Asp

C19H32N8O10 (532.2241)

Gln Glu Ala Trp

C24H32N6O8 (532.2282)

Gln Glu Glu Lys

C21H36N6O10 (532.2493)

Gln Glu Lys Glu

C21H36N6O10 (532.2493)

Gln Glu Arg Thr

C20H36N8O9 (532.2605)

Gln Glu Thr Arg

C20H36N8O9 (532.2605)

Gln Glu Trp Ala

C24H32N6O8 (532.2282)

Gln Lys Glu Glu

C21H36N6O10 (532.2493)

Gln Arg Asp Asp

C19H32N8O10 (532.2241)

Gln Arg Glu Thr

C20H36N8O9 (532.2605)

Gln Arg Thr Glu

C20H36N8O9 (532.2605)

Gln Thr Glu Arg

C20H36N8O9 (532.2605)

Gln Thr Arg Glu

C20H36N8O9 (532.2605)

Gln Trp Ala Glu

C24H32N6O8 (532.2282)

Gln Trp Glu Ala

C24H32N6O8 (532.2282)

Arg Asp Asp Lys

C20H36N8O9 (532.2605)

Arg Asp Asp Gln

C19H32N8O10 (532.2241)

Arg Asp Glu Asn

C19H32N8O10 (532.2241)

Arg Asp Gly Trp

C23H32N8O7 (532.2394)

Arg Asp Lys Asp

C20H36N8O9 (532.2605)

Arg Asp Asn Glu

C19H32N8O10 (532.2241)

Arg Asp Gln Asp

C19H32N8O10 (532.2241)

Arg Asp Trp Gly

C23H32N8O7 (532.2394)

Arg Glu Asp Asn

C19H32N8O10 (532.2241)

Arg Glu Asn Asp

C19H32N8O10 (532.2241)

Arg Glu Gln Thr

C20H36N8O9 (532.2605)

Arg Glu Thr Gln

C20H36N8O9 (532.2605)

Arg Gly Asp Trp

C23H32N8O7 (532.2394)

Arg Gly Trp Asp

C23H32N8O7 (532.2394)

Arg Lys Asp Asp

C20H36N8O9 (532.2605)

Arg Asn Asp Glu

C19H32N8O10 (532.2241)

Arg Asn Glu Asp

C19H32N8O10 (532.2241)

Arg Gln Asp Asp

C19H32N8O10 (532.2241)

Arg Gln Glu Thr

C20H36N8O9 (532.2605)

Arg Gln Thr Glu

C20H36N8O9 (532.2605)

Arg Thr Glu Gln

C20H36N8O9 (532.2605)

Arg Thr Gln Glu

C20H36N8O9 (532.2605)

Arg Trp Asp Gly

C23H32N8O7 (532.2394)

Arg Trp Gly Asp

C23H32N8O7 (532.2394)

Ser Thr Tyr Tyr

C25H32N4O9 (532.2169)

Ser Tyr Thr Tyr

C25H32N4O9 (532.2169)

Ser Tyr Tyr Thr

C25H32N4O9 (532.2169)

Thr Glu Phe His

C24H32N6O8 (532.2282)

Thr Glu His Phe

C24H32N6O8 (532.2282)

Thr Glu Gln Arg

C20H36N8O9 (532.2605)

Thr Glu Arg Gln

C20H36N8O9 (532.2605)

Thr Phe Glu His

C24H32N6O8 (532.2282)

Thr Phe His Glu

C24H32N6O8 (532.2282)

Thr His Glu Phe

C24H32N6O8 (532.2282)

Thr His Phe Glu

C24H32N6O8 (532.2282)

Thr Gln Glu Arg

C20H36N8O9 (532.2605)

Thr Gln Arg Glu

C20H36N8O9 (532.2605)

Thr Arg Glu Gln

C20H36N8O9 (532.2605)

Thr Ser Tyr Tyr

C25H32N4O9 (532.2169)

Thr Tyr Ser Tyr

C25H32N4O9 (532.2169)

Thr Tyr Tyr Ser

C25H32N4O9 (532.2169)

Val Asp His Tyr

C24H32N6O8 (532.2282)

Val Asp Asn Trp

C24H32N6O8 (532.2282)

Val Asp Trp Asn

C24H32N6O8 (532.2282)

Val Asp Tyr His

C24H32N6O8 (532.2282)

Val Phe His Met

C25H36N6O5S (532.2468)

Val Phe Met His

C25H36N6O5S (532.2468)

Val His Asp Tyr

C24H32N6O8 (532.2282)

Val His Phe Met

C25H36N6O5S (532.2468)

Val His Met Phe

C25H36N6O5S (532.2468)

Val His Tyr Asp

C24H32N6O8 (532.2282)

Val Met Phe His

C25H36N6O5S (532.2468)

Val Met His Phe

C25H36N6O5S (532.2468)

Val Asn Asp Trp

C24H32N6O8 (532.2282)

Val Asn Trp Asp

C24H32N6O8 (532.2282)

Val Trp Asp Asn

C24H32N6O8 (532.2282)

Val Trp Asn Asp

C24H32N6O8 (532.2282)

Val Tyr Asp His

C24H32N6O8 (532.2282)

Val Tyr His Asp

C24H32N6O8 (532.2282)

Trp Ala Ala Trp

C28H32N6O5 (532.2434)

Trp Ala Glu Gln

C24H32N6O8 (532.2282)

Trp Ala Gln Glu

C24H32N6O8 (532.2282)

Trp Ala Trp Ala

C28H32N6O5 (532.2434)

Trp Cys Lys Pro

C25H36N6O5S (532.2468)

Trp Cys Pro Lys

C25H36N6O5S (532.2468)

Trp Asp Gly Arg

C23H32N8O7 (532.2394)

Trp Asp Asn Val

C24H32N6O8 (532.2282)

Trp Asp Arg Gly

C23H32N8O7 (532.2394)

Trp Asp Val Asn

C24H32N6O8 (532.2282)

Trp Glu Ala Gln

C24H32N6O8 (532.2282)

Trp Glu Gln Ala

C24H32N6O8 (532.2282)

Trp Gly Asp Arg

C23H32N8O7 (532.2394)

Trp Gly Arg Asp

C23H32N8O7 (532.2394)

Trp Lys Cys Pro

C25H36N6O5S (532.2468)

Trp Lys Pro Cys

C25H36N6O5S (532.2468)

Trp Asn Asp Val

C24H32N6O8 (532.2282)

Trp Asn Val Asp

C24H32N6O8 (532.2282)

Trp Pro Cys Lys

C25H36N6O5S (532.2468)

Trp Pro Lys Cys

C25H36N6O5S (532.2468)

Trp Gln Ala Glu

C24H32N6O8 (532.2282)

Trp Gln Glu Ala

C24H32N6O8 (532.2282)

Trp Arg Asp Gly

C23H32N8O7 (532.2394)

Trp Arg Gly Asp

C23H32N8O7 (532.2394)

Trp Val Asp Asn

C24H32N6O8 (532.2282)

Trp Val Asn Asp

C24H32N6O8 (532.2282)

Trp Trp Ala Ala

C28H32N6O5 (532.2434)

Tyr Asp His Val

C24H32N6O8 (532.2282)

Tyr Asp Val His

C24H32N6O8 (532.2282)

Tyr Phe Phe Gly

C29H32N4O6 (532.2322)

Tyr Phe Gly Phe

C29H32N4O6 (532.2322)

Tyr Gly Phe Phe

C29H32N4O6 (532.2322)

Tyr His Asp Val

C24H32N6O8 (532.2282)

Tyr His Val Asp

C24H32N6O8 (532.2282)

Tyr Ser Thr Tyr

C25H32N4O9 (532.2169)

Tyr Ser Tyr Thr

C25H32N4O9 (532.2169)

Tyr Thr Ser Tyr

C25H32N4O9 (532.2169)

Tyr Thr Tyr Ser

C25H32N4O9 (532.2169)

Tyr Val Asp His

C24H32N6O8 (532.2282)

Tyr Val His Asp

C24H32N6O8 (532.2282)

Tyr Tyr Ser Thr

C25H32N4O9 (532.2169)

Tyr Tyr Thr Ser

C25H32N4O9 (532.2169)

PTVNC

C21H36N6O8S (532.2315)

Austalide D

C28H36O10 (532.2308)

Austalide E

C28H36O10 (532.2308)

NOMILINIC ACID

C28H36O10 (532.2308)

BENZOIC ACID, 4-[4-[(3R)-3-[[[2-OXO-2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]ETHYL]AMINO]CARBONYL]-1-PYRROLIDINYL]-1-PIPERIDINYL]-, METHYL ESTER

C27H31F3N4O4 (532.2297)

Rubrene

C42H28 (532.2191)

Sunitinib malate

C26H33FN4O7 (532.2333)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D006133 - Growth Substances > D006131 - Growth Inhibitors

dde-lys(fmoc)-oh

C31H36N2O6 (532.2573)

Fmoc-Lys(Dde)-OH

C31H36N2O6 (532.2573)

Nickel, dichlorobis(tributylphosphine)-

C24H54Cl2NiP2 (532.2431)

Fmoc-L-Dap(ivDde)-OH

C31H36N2O6 (532.2573)

Bis(tert-butoxy)bis(1-methoxy-2-methyl-2-propoxy)hafnium(IV)

C18H40O6Hf (532.229)

RHODIUM(III) 2-ETHYLHEXANOATE

C24H45O6Rh (532.2271)

Onvansertib

C24H27F3N8O3 (532.2158)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C177899 - PLK1 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1,2,4-triazolo(4,3-a)pyridin-3-yl)ethynyl)-

C29H27F3N6O (532.2198)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

Ametantrone acetate

C26H36N4O8 (532.2533)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents

2-((2-((1-(2-(Dimethylamino)acetyl)-5-methoxyindolin-6-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-6-fluoro-N-methylbenzamide

C27H29FN8O3 (532.2347)

Ponatinib

C29H27F3N6O (532.2198)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents

(2R,6S)-2-amino-6-[[(4R)-4-[[(2S)-2-aminopropanoyl]amino]-4-carboxybutanoyl]amino]-7-[[(2R)-1-[[(1R)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-7-oxoheptanoic acid

C21H36N6O10 (532.2493)

methyl (2S,3R,4S)-3-ethyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylate

C27H36N2O9 (532.2421)

4-[[2-(3-carboxypropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(E)-2-(5-oxo-2H-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-4-oxobutanoic acid

C28H36O10 (532.2308)

PA(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C25H41O10P (532.2437)

PA(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C25H41O10P (532.2437)

PA(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C25H41O10P (532.2437)

PA(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C25H41O10P (532.2437)

PA(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C25H41O10P (532.2437)

lucibufagin C

C28H36O10 (532.2308)

8RL82T4Cqt

C28H36O10 (532.2308)

N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide

C29H32N4O6 (532.2322)

(4-methoxyphenyl) N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

(4-methoxyphenyl) N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(4-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-isoxazolecarboxamide

C29H32N4O6 (532.2322)

(4-methoxyphenyl) N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

(2S)-2-[(4S,5R)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2R)-2-[(4S,5S)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2S)-2-[(4R,5S)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(4-methoxyphenyl) N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

(4-methoxyphenyl) N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

(4-methoxyphenyl) N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

N-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-4-fluoro-N-methylbenzenesulfonamide

C26H33FN4O5S (532.2156)

(2R)-2-[(4S,5R)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2R)-2-[(4R,5S)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2S)-2-[(4S,5S)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2S)-2-[(4R,5R)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

(2R)-2-[(4R,5R)-8-(2-methoxyphenyl)-4-methyl-5-[[methyl(4-oxanylmethyl)amino]methyl]-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H40N2O6S (532.2607)

2-[(3S,6aS,8R,10aS)-1-[(2-fluorophenyl)-oxomethyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H33FN2O5 (532.2373)

(4-methoxyphenyl) N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N-methylcarbamate

C31H36N2O6 (532.2573)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C25H41O10P (532.2437)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C25H41O10P (532.2437)

PA 14:1/8:3;O2

C25H41O10P (532.2437)

PA 18:3/4:1;O2

C25H41O10P (532.2437)

PA 22:4;O2

C25H41O10P (532.2437)

ST 18:1;O7;GlcA

C24H36O13 (532.2156)

ST 19:0;O6;GlcA

C25H40O12 (532.252)

ST 22:5;O4;GlcA

C28H36O10 (532.2308)

ST 18:2;O8;Hex

C24H36O13 (532.2156)

ST 19:1;O7;Hex

C25H40O12 (532.252)

ST 22:6;O5;Hex

C28H36O10 (532.2308)

ST 25:2;O7;S

C25H40O10S (532.2342)

ST 29:6;O4;S

C29H40O7S (532.2495)

IPN60090

C24H27F3N8O3 (532.2158)

IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1?(GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].

(1r,2r,3ar,5r,13r,13as)-1,3a,13-tris(acetyloxy)-2,5,8,8-tetramethyl-12-methylidene-4,9-dioxo-1h,3h,5h,13h,13ah-cyclopenta[12]annulen-2-yl acetate

C28H36O10 (532.2308)

(1s,2s,5s,6s,7s,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2r,3s,5s,6s,8r,10s,11s,12r,14r,15s,16r,19s,21r)-6-(furan-3-yl)-3,12,16,19-tetrahydroxy-5,11,15-trimethyl-4-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O10 (532.2308)

11-isopropyl-4,7,14-trimethyl-18-(sec-butyl)-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol

C25H36N6O5S (532.2468)

(1s,2s,4r,5s,6r,7r,9r,12s)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(4s)-4-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}but-1-en-1-yl]-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one

C25H40O12 (532.252)

3-(3,4-dihydroxyphenyl)-n-[4,7,10-trihydroxy-2,9,13-trimethyl-6-(2-methylpropyl)-14-oxo-1-oxa-5,8,11-triazacyclotetradeca-4,7,10-trien-3-yl]prop-2-enimidic acid

C26H36N4O8 (532.2533)

(1r,2s,4r,5r,6s,7s,9s,12r)-4,7-bis(acetyloxy)-2,12-dihydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl (2r,3s)-3-phenyloxirane-2-carboxylate

C28H36O10 (532.2308)

methyl (14e)-19-[(3,4-dimethoxybenzoyloxy)methyl]-14-ethylidene-18-oxa-2,12-diazahexacyclo[9.6.1.1⁹,¹⁵.0¹,⁹.0³,⁸.0¹²,¹⁷]nonadeca-3,5,7-triene-19-carboxylate

C30H32N2O7 (532.2209)

(9s,10r)-4,5,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl (2e)-3-phenylprop-2-enoate

C32H36O7 (532.2461)

12-hydroxyamoorastatone

C28H36O10 (532.2308)

{"Ingredient_id": "HBIN000872","Ingredient_name": "12-hydroxyamoorastatone","Alias": "NA","Ingredient_formula": "C28H36O10","Ingredient_Smile": "CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C4C(=O)CC5C6=COC=C6)C)O)C)O)C)O)O","Ingredient_weight": "532.6 g/mol","OB_score": "NA","CAS_id": "152013-84-8","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9364","PubChem_id": "101672375","DrugBank_id": "NA"}

(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one

C25H40O12 (532.252)

{"Ingredient_id": "HBIN010856","Ingredient_name": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethylcyclohex-2-en-1-one","Alias": "(4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-1-cyclohex-2-enone; (4R)-4-hydroxy-4-[(E,3S)-3-hydroxybut-1-enyl]-3,5,5-trimethyl-cyclohex-2-en-1-one","Ingredient_formula": "C25H40O12","Ingredient_Smile": "NA","Ingredient_weight": "532.58","OB_score": "30.24475007","CAS_id": "81425-28-7","SymMap_id": "SMIT13678","TCMID_id": "NA","TCMSP_id": "MOL012966","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

methyl 12-[1-(2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate

C28H36O10 (532.2308)

(1r,2r,4s,16r,17s,18r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-18-yl acetate

C28H36O10 (532.2308)

1-ethenyl-6,13-dihydroxy-15-(7-hydroxy-2,8-dimethyl-9,10-dihydrophenanthren-3-yl)-7,13-dimethyltetracyclo[10.2.2.0²,¹¹.0³,⁸]hexadeca-2(11),3,5,7-tetraen-14-one

C36H36O4 (532.2613)

(1s,2s,4r,5s,6s,9s,10s,11r,13r,14r,15s,18s,20r)-6-(furan-3-yl)-4,11,15,18-tetrahydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate

C28H36O10 (532.2308)

(3s)-5-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-2-(hydroxymethyl)-6-{[(2r)-4-[(1s)-2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl]oxy}oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C25H40O12 (532.252)

(1ar,3r,3ar,4r,5r,6r,7as)-4,5-bis(acetyloxy)-6-[(1s,6r)-6-(2-methoxy-2-oxoethyl)-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxirene-3-carboxylic acid

C28H36O10 (532.2308)

5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1r,2r,4r,5s,6s,7s,9s,12r)-4,5,12-tris(acetyloxy)-6-(hydroxymethyl)-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1r,2r,4s,16r,17s,18r,20s)-18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

C28H36O10 (532.2308)

7,8,12-tris(acetyloxy)-2-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate

C28H36O10 (532.2308)

(1r,12s,13s,15r)-1-ethenyl-6,13-dihydroxy-15-(7-hydroxy-2,8-dimethyl-9,10-dihydrophenanthren-3-yl)-7,13-dimethyltetracyclo[10.2.2.0²,¹¹.0³,⁸]hexadeca-2(11),3,5,7-tetraen-14-one

C36H36O4 (532.2613)

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[3-(hydroxymethyl)-2-(3-methylbut-2-en-1-yl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenoxy]oxane-3,4,5-triol

C24H36O13 (532.2156)

(1r,2s,4r,5s,6r,7r,9s,12s)-4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1r,2s,4r,5r,8r,9s,11r)-2-({[(1r,3s,5r,7s,8s,9s)-8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C28H36O10 (532.2308)

(1r,2r,4s,15s,16s,17r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate

C28H36O10 (532.2308)

5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-8-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1r,2s,3r,4s,6r,7r,8r,9r,12s,13s)-9,12-bis(acetyloxy)-3-(chloromethyl)-3,13-dihydroxy-6-isopropyl-9,13-dimethyl-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl acetate

C26H41ClO9 (532.2439)

(1r,2s,4r,5s,6r,7s,8r,9r)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

6-(furan-3-yl)-4,11,15,18-tetrahydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate

C28H36O10 (532.2308)

(4r)-3,5,5-trimethyl-4-[(1e,3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}but-1-en-1-yl]cyclohex-2-en-1-one

C25H40O12 (532.252)

(1r,7ar,9s,11br)-1-(acetyloxy)-9-[(s)-furan-3-yl(hydroxy)methyl]-5,5,7a,9,11b-pentamethyl-3,7-dioxo-hexahydro-1h-spiro[naphtho[2,1-c]oxepine-8,2'-oxirane]-3'-carboxylic acid

C28H36O10 (532.2308)

4-(3-{[4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}but-1-en-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one

C25H40O12 (532.252)

2,9-bis(acetyloxy)-4,8,12,17-tetramethyl-5,16-dioxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadeca-6,12-dien-10-yl butanoate

C28H36O10 (532.2308)

(1s,2s,5s,6s,7s,9r,12r)-7,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate

C28H36O10 (532.2308)

4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

2-(hydroxymethyl)-6-[3-(hydroxymethyl)-2-(3-methylbut-2-en-1-yl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenoxy]oxane-3,4,5-triol

C24H36O13 (532.2156)

5-{[3,5-dihydroxy-2-(hydroxymethyl)-6-({4-[2-(hydroxymethyl)-6,6-dimethyl-4-oxocyclohex-2-en-1-yl]butan-2-yl}oxy)oxan-4-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C25H40O12 (532.252)

(1s,2r,4s,5r,8r,9r,11s)-2-({[(1s,3r,5s,7r,8s,9s)-8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C28H36O10 (532.2308)

4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol

C25H36N6O5S (532.2468)

(4s,7r,8s,11s,15s,18s)-4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),16,19(22)-heptaene-2,9,16-triol

C25H36N6O5S (532.2468)

4,5-bis(acetyloxy)-6-[6-(2-methoxy-2-oxoethyl)-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxirene-3-carboxylic acid

C28H36O10 (532.2308)

(2e)-4-[(1r,5s,7r)-1-[(2s,3e,5r,6z)-7-chloro-5,9-dihydroxynona-3,6-dien-2-yl]-6-azaspiro[4.5]decan-7-yl]-2-methyl-n-(2-sulfoethyl)but-2-enimidic acid

C25H41ClN2O6S (532.2374)

6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O10 (532.2308)

(1'r,2's,3r,3'r,4s,5'r,10's,11's,14's)-11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate

C28H36O10 (532.2308)

(1r,2s,4r,5s,6r,7s,8r,9r)-4,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

4,5,14,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl 3-phenylprop-2-enoate

C32H36O7 (532.2461)

(1s,2s,5r,6r)-5,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-2-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid

C31H36N2O6 (532.2573)

7,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate

C28H36O10 (532.2308)

(1'r,2s,2's,4's,6'r,7'r,11'r,12's,14's,16'r,20'r,23's,25'r)-12',14',25'-trihydroxy-4,7',22',22'-tetramethyl-3',10',17',21'-tetraoxaspiro[furan-2,9'-heptacyclo[12.11.0.0²,⁴.0²,¹¹.0⁶,¹¹.0¹⁶,²⁰.0¹⁶,²³]pentacosane]-5,18'-dione

C28H36O10 (532.2308)

(2s)-2-amino-n-[(2s)-1-{[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-(1h-indol-3-yl)propanoyl]oxy}-3-(1h-indol-3-yl)-1-oxopropan-2-yl]propanimidic acid

C28H32N6O5 (532.2434)

11,13,24-trihydroxy-7,21,21-trimethyl-8-(4-methyl-5-oxo-2h-furan-2-yl)-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

C28H36O10 (532.2308)

(3s)-3-(acetyloxy)-3-[(1r,2r,5r,6r,7r,10s,11s,14s)-11-(furan-3-yl)-5-(2-hydroxypropan-2-yl)-2,6,10-trimethyl-3,13-dioxo-12,15-dioxatetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan-6-yl]propanoic acid

C28H36O10 (532.2308)

12',14',25'-trihydroxy-4,7',22',22'-tetramethyl-3',10',17',21'-tetraoxaspiro[furan-2,9'-heptacyclo[12.11.0.0²,⁴.0²,¹¹.0⁶,¹¹.0¹⁶,²⁰.0¹⁶,²³]pentacosane]-5,18'-dione

C28H36O10 (532.2308)

5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O10 (532.2308)

1-ethenyl-5,13-dihydroxy-15-(7-hydroxy-2,8-dimethyl-9,10-dihydrophenanthren-4-yl)-6,13-dimethyltetracyclo[10.2.2.0²,¹¹.0³,⁸]hexadeca-2(11),3,5,7-tetraen-14-one

C36H36O4 (532.2613)

methyl (1s,12s,19s)-12-[(1s)-1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

(1s,2r,5s,6s,7r,8r,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-8-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2r,4s,5r,6r,7s,9r,12r)-5,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

2-({[8-(acetyloxy)-9-hydroxy-2,4,6-trioxatricyclo[3.3.1.0³,⁷]nonan-5-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C28H36O10 (532.2308)

(2e,4e,6e,8e)-9-[(2s)-2-hydroxy-4-{[(2e,4e,6e)-1-hydroxy-8-methylnona-2,4,6-trien-1-ylidene]amino}-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)nona-2,4,6,8-tetraenimidic acid

C30H32N2O7 (532.2209)

18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

C28H36O10 (532.2308)

11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate

C28H36O10 (532.2308)

(1r,2s,5r,6s)-2,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-5-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid

C31H36N2O6 (532.2573)

methyl (1r,12s,19r)-12-[(1r)-1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

methyl 12-[1-(7-methoxy-2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

2,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-5-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid

C31H36N2O6 (532.2573)

(4s)-4-[(1e,3r)-3-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}but-1-en-1-yl]-4-hydroxy-3,5,5-trimethylcyclohex-2-en-1-one

C25H40O12 (532.252)

(1r,2r,5r,6r,7r,8r,9s,12r)-7,8,12-tris(acetyloxy)-2-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate

C28H36O10 (532.2308)

4,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2s,8s,17s,19r)-12-hydroxy-19-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C32H36O7 (532.2461)

(20r,24s,26s)-7-ethenyl-12-ethyl-19,20-dihydroxy-6,11,26,27-tetramethyl-2,16,28,29-tetraazaheptacyclo[15.7.1.1³,²⁴.1⁵,⁸.1¹⁰,¹³.1¹⁵,¹⁸.0²⁰,²⁵]nonacosa-1(25),3,5(29),6,8,10(28),11,13,15(27),16,18-undecaen-21-one

C33H32N4O3 (532.2474)

(1r,2r,4s,5s,6r,7s,9s,12s)-4,12-bis(acetyloxy)-6-[(acetyloxy)methyl]-5-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15r,16s,19s,21r)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O10 (532.2308)

(1r,2r,6s,7r,9s)-13-(1,6-dihydroxyhexa-2,4-dien-1-ylidene)-6,7,12-trihydroxy-4-(6-hydroxyhex-4-enoyl)-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]tridec-11-ene-3,10-dione

C28H36O10 (532.2308)

(1s,2s,5s,6s,7s,8s,9r,12r)-7,8,12-tris(acetyloxy)-2-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate

C28H36O10 (532.2308)

13-(1,6-dihydroxyhexa-2,4-dien-1-ylidene)-6,7,12-trihydroxy-4-(6-hydroxyhex-4-enoyl)-2,6,9,11-tetramethyl-8-oxatricyclo[7.4.0.0²,⁷]tridec-11-ene-3,10-dione

C28H36O10 (532.2308)

2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-18-yl acetate

C28H36O10 (532.2308)

methyl (1r,9s,11s,14e,15s,17s,19r)-19-[(3,4-dimethoxybenzoyloxy)methyl]-14-ethylidene-18-oxa-2,12-diazahexacyclo[9.6.1.1⁹,¹⁵.0¹,⁹.0³,⁸.0¹²,¹⁷]nonadeca-3,5,7-triene-19-carboxylate

C30H32N2O7 (532.2209)

(1s,2s,4r,5s,6s,9s,10s,11r,13r,14s,15r,18s,20r)-6-(furan-3-yl)-4,11,15,18-tetrahydroxy-5,10,14-trimethyl-3,8-dioxo-16-oxapentacyclo[12.3.3.0¹,¹³.0²,¹⁰.0⁵,⁹]icosan-20-yl acetate

C28H36O10 (532.2308)

(1s,2r,4s,5r,6s,7s,8s,9r)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

(1s,2s,3s,4r,8s,9r,10s,12z,14s,17r)-2,9-bis(acetyloxy)-4,8,12,17-tetramethyl-5,16-dioxo-15,18-dioxatetracyclo[12.4.0.0¹,¹⁷.0³,⁸]octadeca-6,12-dien-10-yl butanoate

C28H36O10 (532.2308)

5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

12-hydroxy-19-(4-hydroxy-3-methylbut-2-en-1-yl)-8,21,21-trimethyl-5-(3-methylbut-2-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C32H36O7 (532.2461)

methyl (1r,12r,19r)-12-[(1s)-1-(2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

(3r)-3-(acetyloxy)-3-[(1r,2r,5r,6s,7r,10s,11s,14s)-11-(furan-3-yl)-5-(2-hydroxypropan-2-yl)-2,6,10-trimethyl-3,13-dioxo-12,15-dioxatetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan-6-yl]propanoic acid

C28H36O10 (532.2308)

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-(4-methyl-5-oxo-2h-furan-2-yl)-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

C28H36O10 (532.2308)

(2e)-3-(3,4-dihydroxyphenyl)-n-[(2r,3s,6s,9r,13s)-4,7,10-trihydroxy-2,9,13-trimethyl-6-(2-methylpropyl)-14-oxo-1-oxa-5,8,11-triazacyclotetradeca-4,7,10-trien-3-yl]prop-2-enimidic acid

C26H36N4O8 (532.2533)

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-[(2s)-4-methyl-5-oxo-2h-furan-2-yl]-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

C28H36O10 (532.2308)

(1s,2r,4s,5r,6s,7s,8s,9s)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O10 (532.2308)

5,6-bis(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)-2-(piperidine-1-carbonyl)cyclohex-3-ene-1-carboximidic acid

C31H36N2O6 (532.2573)